These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35086103)

  • 1. Growth Differentiation Factor-15 and Syndecan-1 Are Potential Biomarkers of Cardiac and Renal Involvement in Classical Fabry Disease under Enzyme Replacement Therapy.
    Gregório PC; Biagini G; Cunha RSD; Budag J; Martins AM; Rivas LV; Schiefer EM; Sánchez-Niño MD; Ortiz A; Stinghen AEM; Barreto FC
    Kidney Blood Press Res; 2022; 47(4):229-238. PubMed ID: 35086103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?
    Ozer H; Baloglu I; Topkac A; Ozturk Y; Yonet F; Daglı F; Kilinc İ; Turkmen K
    Nefrologia (Engl Ed); 2024; 44(2):217-223. PubMed ID: 37179210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
    Chen Z; Yin B; Jiao J; Ye T
    BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
    Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
    Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
    Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
    Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy.
    Chen KH; Chien Y; Wang KL; Leu HB; Hsiao CY; Lai YH; Wang CY; Chang YL; Lin SJ; Niu DM; Chiou SH; Yu WC
    Can J Cardiol; 2016 Oct; 32(10):1221.e1-1221.e9. PubMed ID: 26919792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy.
    Chen KH; Chou YC; Hsiao CY; Chien Y; Wang KL; Lai YH; Chang YL; Niu DM; Yu WC
    Biochem Biophys Res Commun; 2017 Apr; 486(2):293-299. PubMed ID: 28300554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.
    Lenders M; Schmitz B; Stypmann J; Duning T; Brand SM; Kurschat C; Brand E
    Nephrol Dial Transplant; 2017 Dec; 32(12):2090-2097. PubMed ID: 27679524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
    Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
    Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
    Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
    Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy.
    Yonishi H; Namba-Hamano T; Hamano T; Hotta M; Nakamura J; Sakai S; Minami S; Yamamoto T; Takahashi A; Kobayashi W; Maeda I; Hidaka Y; Takabatake Y; Sakai N; Isaka Y
    Nephrol Dial Transplant; 2021 Dec; 37(1):53-62. PubMed ID: 33367839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease.
    Nowak A; Koch G; Huynh-Do U; Siegenthaler M; Marti HP; Pfister M
    Kidney Blood Press Res; 2017; 42(1):1-15. PubMed ID: 28253518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.